Epidemiology of acute myelogenous leukemia.

Abstract:

:The epidemiologic literature suggests that environmental exposures, familial susceptibility, and cytogenetic changes affect AML risk in childhood and adulthood. Unfortunately, many studies are limited by inadequate sample sizes, imprecise case definition, or inadequate exposure measurement. Few studies have singled out AML alone, either because of insufficient numbers or because methods of case ascertainment made it difficult to distinguish specific cell types. Studies of total leukemia or all acute leukemias offer insights into potential risk factors for AML, but may also be misleading in instances when few AML patients were actually included. Future studies should include adequate numbers of patients with AML. At the same time, further refinement of case definition through parameters such as specific cytogenetic changes may make risk factor identification in epidemiologic studies more likely.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Sandler DP

subject

Has Abstract

pub_date

1987-12-01 00:00:00

pages

359-64

issue

4

eissn

0093-7754

issn

1532-8708

journal_volume

14

pub_type

杂志文章,评审
  • Evaluating temsirolimus activity in multiple tumors: a review of clinical trials.

    abstract::Activation of mammalian target of rapamycin (mTOR) signaling occurs in a wide variety of human tumors and can lead to increased susceptibility to mTOR inhibitors. Temsirolimus, a novel analog of rapamycin, has shown promising preclinical and early clinical anti-tumor activity in various solid and hematologic tumor typ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2009.10.010

    authors: Dancey JE,Curiel R,Purvis J

    更新日期:2009-12-01 00:00:00

  • The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.

    abstract::The supplanting of radical mastectomy by simple mastectomy and then by lumpectomy plus radiation, the use of adjuvant therapy to alter the natural course of breast and colorectal cancer, the use of tamoxifen for the prevention of breast cancer, and the dramatic improvement in survival demonstrated with the use of the ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2008.07.005

    authors: Wickerham DL,O'Connell MJ,Costantino JP,Cronin WM,Paik S,Geyer CE Jr,Ganz PA,Petrelli N,Mamounas EP,Julian TB,Wolmark N

    更新日期:2008-10-01 00:00:00

  • Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.

    abstract::Combination antimicrotubule therapy with estramustine phosphate (EMP) and vinblastine has reproducible activity in metastatic hormone-refractory prostate cancer (HRPC) with an objective response rate of 31%. Although paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 24-hour infusion was inactive in HR...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Hudes GR,Nathan FE,Khater C,Greenberg R,Gomella L,Stern C,McAleer C

    更新日期:1995-10-01 00:00:00

  • Third-line salvage chemotherapy in Hodgkin's disease.

    abstract::CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35%, and partial remission, 25%) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible. ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Bonadonna G,Viviani S,Valagussa P,Bonfante V,Santoro A

    更新日期:1985-03-01 00:00:00

  • Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.

    abstract::Adjuvant chemotherapy has a real but modest impact on the disease-free and overall survival of patients with breast cancer. Recent attempts to improve its effectiveness have focused on dose intensity and new agents. Sequential therapy maximized dose intensity while limiting overlapping toxicity. Sequential therapy usi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Hudis C,Seidman A,Raptis G,Fennelly D,Gilewski T,Baselga J,Theodoulou M,Sklarin N,Moynahan M,Surbone A,Currie V,Lebwohl D,Uhlenhopp M,Crown J,Norton L

    更新日期:1996-02-01 00:00:00

  • Novel radiation therapy approaches for breast cancer treatment.

    abstract::The role of radiation therapy in the management of breast cancer continues to evolve. For patients with early stage breast cancer, hypofractionated whole breast irradiation following breast conserving surgery now represents the standard of care based on randomized data with long-term efficacy and toxicity outcomes. Pa...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2020.05.003

    authors: Shah C,Bauer-Nilsen K,McNulty RH,Vicini F

    更新日期:2020-08-01 00:00:00

  • Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.

    abstract::Non-small cell lung cancer (NSCLC) remains a malignancy that is refractory to most currently available chemotherapeutic agents. The most frequently used systemic therapy is cisplatin-based combination therapy, which is not always suitable for patients with stage IV disease because of toxicity. Thus, any single agent w...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Manegold C

    更新日期:1998-08-01 00:00:00

  • The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.

    abstract::For patients whose breast cancers are not responsive to endocrine therapy, there are a large number of cytotoxic drugs that will induce a response. In spite of the introduction of new, very active drugs such as the taxanes, vinorelbine, capecitabine, gemcitabine, and trastuzumab, the anthracyclines are still as active...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.09.018

    authors: Robert NJ,Vogel CL,Henderson IC,Sparano JA,Moore MR,Silverman P,Overmoyer BA,Shapiro CL,Park JW,Colbern GT,Winer EP,Gabizon AA

    更新日期:2004-12-01 00:00:00

  • Recent developments in breast cancer therapy.

    abstract::Over the past three decades conceptual approaches to breast cancer have led to improvements in locoregional therapy and early diagnosis. Systematic screening programs with mammography reduce disease-specific mortality by 25% to 30%, while many patients with early breast cancer receive optimal breast-conserving treatme...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hortobagyi GN,Hung MC,Buzdar AU

    更新日期:1999-08-01 00:00:00

  • Interferons and their stimulated genes in the tumor microenvironment.

    abstract::Constitutive expression of interferons (IFNs) and activation of their signaling pathways have pivotal roles in host responses to malignant cells in the tumor microenvironment. IFNs are induced by the innate immune system and in tumors through stimulation of Toll-like receptors (TLRs) and through other signaling pathwa...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.02.002

    authors: Cheon H,Borden EC,Stark GR

    更新日期:2014-04-01 00:00:00

  • Vascular toxicity of antineoplastic agents.

    abstract::Among the various deleterious effects of cancer chemotherapy, vascular toxicity is the least well recognized. This lack of recognition may be because the vasculotoxic phenomena are not unique to antineoplastic agents, can occur in patients without exposure to these agents, and the fact cancer itself may produce a hype...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.11.006

    authors: Shahab N,Haider S,Doll DC

    更新日期:2006-02-01 00:00:00

  • Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.

    abstract::Knowledge of the pharmacokinetics of a drug is essential to the optimal design of the dose and schedule of chemotherapy protocols. As an extension, an understanding of the mechanism of drug action is necessary to construct the optimal strategy for combination chemotherapy. Nucleoside antimetabolites such as fludarabin...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Plunkett W,Gandhi V,Huang P,Robertson LE,Yang LY,Gregoire V,Estey E,Keating MJ

    更新日期:1993-10-01 00:00:00

  • Cooperative Group Trials in the Community Setting.

    abstract::Over the last 40 years the National Cancer Institute (NCI) has created a vibrant public-private partnership for the implementation of NCI-sponsored cooperative group (Network) clinical trials throughout the United States and Canada. Over these four decades, the cancer clinical trials process has become more complex mo...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2015.07.011

    authors: Lloyd Wade J 3rd,Petrelli NJ,McCaskill-Stevens W

    更新日期:2015-10-01 00:00:00

  • Targeting the epigenome for the treatment and prevention of lung cancer.

    abstract::Alterations in chromatin structure resulting from aberrant DNA methylation and perturbations of the histone code profoundly influence gene expression during pulmonary carcinogenesis. Recent studies indicate that DNA demethylating agents and histone deacetylase (HDAC) inhibitors synergistically induce gene expression a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.07.007

    authors: Schrump DS,Nguyen DM

    更新日期:2005-10-01 00:00:00

  • The root causes of pharmacodynamic assay failure.

    abstract::Robust pharmacodynamic assay results are valuable for informing go/no-go decisions about continued development of new anti-cancer agents and for identifying combinations of targeted agents, but often pharmacodynamic results are too incomplete or variable to fulfill this role. Our experience suggests that variable reag...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.06.006

    authors: Ferry-Galow KV,Makhlouf HR,Wilsker DF,Lawrence SM,Pfister TD,Marrero AM,Bigelow KM,Yutzy WH,Ji JJ,Butcher DO,Gouker BA,Kummar S,Chen AP,Kinders RJ,Parchment RE,Doroshow JH

    更新日期:2016-08-01 00:00:00

  • Use of preclinical models to assess the therapeutic potential of new drug candidates for bladder cancer.

    abstract::The purpose of this review is to demonstrate a successful use of preclinical models of bladder cancer to confirm the therapeutic potential of new promising drug candidates. The bladder has long been thought to be an ideal target for investigating therapies. When developing a new antineoplastic pharmaceutical agent, th...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.08.006

    authors: Amit D,Gofrit ON,Matouk I,Birman T,Hochberg A

    更新日期:2012-10-01 00:00:00

  • Response patterns of recurrent glioblastomas treated with tumor-treating fields.

    abstract::Glioblastoma multiforme (GBM) is the most common form of primary malignant brain cancer. Median overall survival (OS) for newly diagnosed patients is only about 12 to 18 months. GBM tumors invariably recur, and there is no widely recognized and effective standard treatment for recurrent GBM. NovoTTF Therapy is a novel...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2014.09.009

    authors: Vymazal J,Wong ET

    更新日期:2014-10-01 00:00:00

  • Introduction to the treatment of lung cancer.

    abstract::Lung cancer represents the leading cause of cancer mortality worldwide. Its incidence has declined in men but is increasing in women, assuring that this largely preventable disease will continue to affect millions. In small cell lung cancer, the advent of chemotherapy in the 1970s and continued refinements in the 1980...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Splinter TA

    更新日期:1997-08-01 00:00:00

  • Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.

    abstract::In a multicenter phase III trial, 267 patients with nonbulky metastatic colorectal cancer who had failed first-line 5-fluorouracil (5-FU) therapy were randomized to receive second-line treatment with either the new topoisomerase agent, irinotecan (Rhône-Poulenc Rorer, Antony, France), or a high-dose infusional 5-FU re...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Van Cutsem E,Blijham GH

    更新日期:1999-02-01 00:00:00

  • Beyond detectable minimal residual disease in chronic lymphocytic leukemia.

    abstract::Lymphoproliferative disorders are characterized by the abnormal accumulation of aberrant lymphocytes, which frequently interfere with the processes associated with immunologic response and hematopoiesis. Chronic lymphocytic leukemia (CLL) has traditionally been considered indolent, with a prolonged clinical course. Ho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.01.026

    authors: Hillmen P

    更新日期:2006-04-01 00:00:00

  • Role of surgery in the treatment of bilio-pancreatic cancer: the European experience.

    abstract::Pancreatic cancer is the eighth most common cancer in Europe, accounting for 4.1% of cancer deaths in men and 4.8% in women. Standardized pancreatoduodenectomy and left pancreatectomy are the gold standard for routine surgical treatment of pancreatic cancer. Total pancreatectomy should be reserved for positive pancrea...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.37379

    authors: Pedrazzoli S,Pasquali C,Sperti C

    更新日期:2002-12-01 00:00:00

  • Intraperitoneal therapy in renal failure.

    abstract::As continuous ambulatory peritoneal dialysis becomes more popular, the science of catheter selection, insertion, and maintenance becomes increasingly necessary. The proper use of and possible complications associated with several currently used catheters are discussed. The pros and cons of single- and double-cuff cath...

    journal_title:Seminars in oncology

    pub_type: 历史文章,杂志文章

    doi:

    authors: Twardowski ZJ

    更新日期:1985-09-01 00:00:00

  • Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.

    abstract::Treatment of hormone-refractory prostate cancer (HRPC) historically has shown limited efficacy. However, taxane-based chemotherapy regimens recently have demonstrated more promising results. Several groups have reported significant efficacy and minimal toxicity in patients with hormone-refractory disease receiving est...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Oh WK,Kantoff PW

    更新日期:1999-10-01 00:00:00

  • Array-based cytogenetic approaches in acute myeloid leukemia: clinical impact and biological insights.

    abstract::Conventional cytogenetic studies have shown that the clinical and biological diversity of acute myeloid leukemia (AML) can be attributed, in part, to distinct chromosome aberrations, several of which are now routinely used for diagnosis, risk stratification, and outcome prediction. Although chromosome banding analysis...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.11.005

    authors: Bullinger L,Fröhling S

    更新日期:2012-02-01 00:00:00

  • Prognostic factors for local control of sarcomas of the soft tissues managed by radiation and surgery.

    abstract::During the past decade, local control of primary sarcomas of the extremities by radiation and conservative surgery has supplanted more radical compartmental resections or amputations. Reviews of others and our published data show that the probability of achieving local control is highly dependent on achieving negative...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Spiro IJ,Gebhardt MC,Jennings LC,Mankin HJ,Harmon DC,Suit HD

    更新日期:1997-10-01 00:00:00

  • Nimotuzumab: beyond the EGFR signaling cascade inhibition.

    abstract::One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activates multiple signaling cascades that promote carcinogenesis and immune evasion. Therefore, these molecules have been extensively targeted in cancer immunotherapy. Beyond EGFR signaling cascade inhibition, some of these agen...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2018.04.008

    authors: Mazorra Z,Chao L,Lavastida A,Sanchez B,Ramos M,Iznaga N,Crombet T

    更新日期:2018-01-01 00:00:00

  • Immunotherapeutic strategies for high-risk bladder cancer.

    abstract::Transitional cell carcinoma (TCC), which is the pathological diagnosis for the majority of bladder cancers, is a solid tumor entity that is responsive to immunotherapy as evidenced by a substantial cure rate documented with the use of intravesical bacillus Calmette-Guérin (BCG) therapy in selected patients with high-g...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.12.004

    authors: Sharma P,Old LJ,Allison JP

    更新日期:2007-04-01 00:00:00

  • In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence.

    abstract::Preliminary clinical studies demonstrated that 5' nor-anhydro-vinblastine, Navelbine (NVB) has a broader antitumor activity and fewer neurotoxic effects than vinblastine or vincristine. The tectal plate anlage of mouse embryos at the earliest stages of neuronal differentiation were used to analyze and compare the effe...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Binet S,Fellous A,Lataste H,Krikorian A,Couzinier JP,Meininger V

    更新日期:1989-04-01 00:00:00

  • MicroRNAs in mutagenesis, genomic instability, and DNA repair.

    abstract::MicroRNAs (miRNAs) are aiding our understanding of cancer biology, and are now coming close to therapeutic use as well. Here, we focus specifically on the interaction between miRNAs and genomic instability. MiRNA regulation is essential to many cellular processes, and escape from this regulatory network seems to be a ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.08.003

    authors: Landau DA,Slack FJ

    更新日期:2011-12-01 00:00:00

  • Treatment of newly diagnosed myeloma: Bortezomib-based triplet.

    abstract::We review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation (ASCT). Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first-line therapy. In one of these trials, VRD demonstrated improved overall su...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2016.11.003

    authors: Rajan AM,Rajkumar SV

    更新日期:2016-12-01 00:00:00